Page Menu

Experimental Therapeutics

The Experimental Therapeutics (ET) Program brings together translational and clinical researchers to discover and validate novel cancer targets, and to develop and test new therapeutics, treatment strategies and biomarkers for cancer. Research in the ET Program aims to:

Guide drug discovery efforts by identifying factors and regulatory pathways that can be targeted to selectively eradicate cancer cells
Develop novel cancer therapeutic agents (e.g., small molecule inhibitors and therapeutic RNAs) and repurpose approved drugs for cancer indications
Develop delivery approaches and systems for cancer therapeutics
Conduct clinical trials to evaluate new chemotherapy treatment options, improve surgical procedures for quality and outcomes improvement, and identify novel markers for diagnostic and prognostic predictors of outcome

Leadership

Getting Results…

Members

Getting Results…

Program Highlights

Getting Results…

Paving the Path for Neuro-Oncology Translational Research: A Conversation with David Cachia, MD

David Cachia, MD talks about future neuro-oncology clinical trials at UMass Chan

Read more

, Experimental Therapeutics,
AIMing to Improve the Response of Melanoma to Immunotherapy

An early-stage research study of immunotherapy in melanoma has received funding from the UMass Cancer Center

Read more

, Experimental Therapeutics,

Experimental Therapeutics

Leadership

Lucio H. Castilla, PhD

Jason Shohet, MD, PhD

Members

Ali Akalin, MD, PhD

Karim Alavi, MD, MPH

Kathleen Arcaro, PhD

Jennifer A. Baima, MD

Bruce A. Barton, PhD

B. Nicolas Bloch, MD

Alexei A. Bogdanov, Jr., PhD, ScD

Michael Brodsky, PhD

David Cachia, MD

Jan Cerny, MD, PhD

Jennifer L. Clark, MD, PhD

April Deng, MD, PhD

Kate H. Dinh, MD, MS

Todd Emrick, PhD

Thomas J. Fitzgerald, MD

Neil Forbes, PhD

Guangping Gao, PhD

Jonathan M. Gerber, MD

Matthew J. Gounis, PhD

Michael R. Green, MD, PhD

Gang Han, PhD

Jeanne Hardy, PhD

John E. Harris, MD, PhD

Lloyd M. Hutchinson, PhD

Anastasia Khvorova, PhD

Ashish Kulkarni, PhD

Jennifer LaFemina, MD

Anne C. Larkin, MD

Michael J. Lee, PhD

James M. Lindberg, MD

David Julian McClements, PhD

Beth A. McCormick, PhD

Mathew J. Most, MD

Peter E. Newburger, MD

Shyam A. Patel, MD, PhD

Muthalagu Ramanathan, MD

Vincent M. Rotello, PhD

William Royer, PhD

Miguel Sena-Esteves, PhD

Leili Shahriyari, PhD

Shirin Sioshansi, MD

Rachid Skouta, PhD

Govind Srimathveeravalli, PhD

S. "Thai" Thayumanavan, PhD

Paul R. Thompson, PhD

Vijay K. Vanguri, MD

William V. Walsh, MD

Jonathan K. Watts, PhD

Giles F. Whalen, MD

Bruce A. Woda, MD

Scot A. Wolfe, PhD

Michelle Yang, MD, PhD

Guodong Zhang, PhD

Susan Zweizig, MD

Paving the Path for Neuro-Oncology Translational Research: A Conversation with David Cachia, MD

AIMing to Improve the Response of Melanoma to Immunotherapy

Research Programs